RNF43 Mutation Detection for Wnt Inhibitor Patient Selection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current Wnt inhibitors are ineffective against tumors with mutations in downstream genes of the Wnt pathway, such as APC, AXIN1/2, and β-catenin, as they do not inhibit Wnt signaling in these cases, highlighting a need for identifying cancer-associated Wnt pathway mutations in upstream components.

Innovation Solution

A method for selecting cancer patients for Wnt inhibitor treatment by detecting inactivating mutations in the RNF43 gene using DNA sequencing or protein analysis methods, allowing for targeted administration of Wnt inhibitors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If Wnt inhibitors targeting upstream components are used, then they can potentially treat tumors with downstream mutations, but they are ineffective against tumors with mutations in downstream genes such as APC, AXIN1/2, and β-catenin

Engineering Contradiction:

Improveeffectiveness against different tumor typesVSAvoidtreatment efficacy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies preliminary action by performing genetic testing for RNF43 mutations before administering Wnt inhibitors. This pre-screening identifies patients whose tumors have upstream pathway mutations, making them responsive to Wnt inhibition therapy, thereby avoiding ineffective treatment in patients with downstream mutations

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent applies local quality by differentiating treatment approaches based on specific genetic characteristics of individual tumors. Rather than applying a uniform Wnt inhibitor regimen to all patients, the treatment is tailored to those with RNF43 mutations, matching the therapeutic mechanism to the specific molecular defect in the tumor

Inventive Principle:

Principle #3Local quality

2Quantity of substance

If Wnt inhibitors are administered without patient selection, then broader treatment coverage is achieved, but treatment efficacy is reduced due to inclusion of patients with downstream mutations

Engineering Contradiction:

Improvenumber of patients treatedVSAvoidoverall treatment success rate

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent uses preliminary genetic screening for RNF43 mutations to select appropriate patients before treatment. This ensures that only patients with tumors likely to respond to Wnt inhibition receive the therapy, maintaining high treatment success rates while treating an adequate number of eligible patients

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentEP3693476B1Cancer patient selection for administration of WNT signaling inhibitors using RNF43 mutation status

Publication Date: 2023.10.18 NOVARTIS AG

Figure 1(a)~1(b)
Figure 2
Figure 2

AI summary

Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation mutation, phosphorylated LRP6, phophorylated Dishevelleds, and the expression of Frizzleds. These biomarkers can be associated with the better outcome for cancer patients treated with Wnt pathway inhibitors.